SEC Form 4 · accession 0001615774-17-003376

Tonix Pharmaceuticals Holding Corp. · TNXP

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — Chief Executive Officer · Director

Period of report

Jun 26, 2017

Accepted (ET)

Jun 26, 2017 · 5:29 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001430306

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock, $0.001 par value	Jun 26, 2017	P	5,000	$4.3999	A	25,000	I	By IRA account
Common Stock, $0.001 par value	holding	—	—		—	13,300	I	By 401(k) plan
Common Stock, $0.001 par value	holding	—	—		—	7,912	D
Common Stock, $0.001 par value	holding	—	—		—	3,100	I	By spouse
Common Stock, $0.001 par value^F1	holding	—	—		—	3	I	By Leder Laboratories, Inc
Common Stock, $0.001 par value^F1	holding	—	—		—	3	I	By Starling Pharmaceuticals, Inc
Common Stock, $0.001 par value^F1	holding	—	—		—	18,463	I	By Lederman & Co., LLC
Common Stock, $0.001 par value^F1	holding	—	—		—	3,246	I	By L&L Technologies, LLC
Common Stock, $0.001 par value^F1	holding	—	—		—	5,898	I	By Targent Pharmaceuticals, LLC

No Table II lines on this filing.